Recent analyst coverage has put Viatris (VTRS) in the spotlight as a value stock, with attention on its cash generation, late stage pipeline, and recent fixed income offerings that add another layer to the investment story.

Viatris has seen momentum build over 2026, with a 27.85% year to date share price return and a 22.07% 90 day share price return. The 1 year total shareholder return of 81.56% reflects how recent fixed income offerings and pipeline updates have fed into a stronger overall investor outcome.

If Viatris has you rethinking where value might appear next in healthcare, it could be worth widening your search to other opportunities through the 38 healthcare AI stocks

With Viatris screens flagging the stock as undervalued on several metrics and analysts seeing upside to current levels, the key question is whether you are still looking at a genuine discount or if the market is already pricing in future growth.

Most Popular Narrative: 59.4% Undervalued

According to one of the most widely followed narratives on Viatris, a fair value of $39.24 versus a last close of $15.93 suggests a sizeable valuation gap that hinges on how investors view its cash flows, earnings path, and transition story.

The early years were tough: many Upjohn products were in natural decline, the generics market is brutally competitive, and the merger came with a heavy debt load. Investors saw a company that needed to shrink rather than grow, and the stock lagged for years. But beneath the surface, something different was happening. Viatris continued to generate massive cash flows and used them to reduce debt, stabilize margins, and invest selectively in new areas such as biosimilars and cardiovascular treatments.

Want to see how this cash flow story feeds into that $39.24 valuation? The narrative leans heavily on future profitability, margin stability, and a re rated earnings profile. Curious which specific earnings and revenue assumptions carry the most weight in that fair value calculation? The full narrative lays out those building blocks in detail.

Result: Fair Value of $39.24 (UNDERVALUED)

However, Viatris still faces risks, including pressure on generic drug pricing and the possibility that earnings or cash flows fall short of current assumptions.

Next Steps

If the mix of optimism and caution around Viatris resonates with you, now is an appropriate moment to review the underlying data yourself and decide where you stand. You can begin with the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Viatris?

If Viatris has sharpened your focus on value and income, do not stop here. Broaden your watchlist and pressure test your thesis against fresh opportunities.

• Zero in on quality opportunities that still trade at a discount by scanning through the 44 high quality undervalued stocks.
• Strengthen your income potential by reviewing companies in the 7 dividend fortresses that combine higher yields with staying power.
• Lower the chance of unpleasant surprises by focusing on financially resilient businesses using the 69 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.